Bendectin and birth defects
the challenges of mass toxic substances litigation
by Green, Michael D.
Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation.
Check nearby libraries
Buy this book
Previews available in: English
| Edition | Availability |
|---|---|
1
Bendectin and birth defects: the challenges of mass toxic substances litigation
1996, University of Pennsylvania Press
in English
0812232577 9780812232578
|
aaaa
|
Book Details
Edition Notes
Includes bibliographical references (p. [353]-359) and index.
Classifications
The Physical Object
Edition Identifiers
Work Identifiers
Community Reviews (0)
Lists
History
- Created April 1, 2008
- 9 revisions
Wikipedia citation
×CloseCopy and paste this code into your Wikipedia page. Need help?
| July 19, 2025 | Edited by MARC Bot | import existing book |
| December 7, 2022 | Edited by ImportBot | import existing book |
| June 5, 2022 | Edited by ImportBot | import existing book |
| January 27, 2022 | Edited by ImportBot | import existing book |
| April 1, 2008 | Created by an anonymous user | Imported from Scriblio MARC record |